| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 10 | 2026 | 638 | 1.710 |
Why?
|
| Oropharyngeal Neoplasms | 6 | 2025 | 260 | 1.400 |
Why?
|
| Head Movements | 2 | 2022 | 18 | 0.760 |
Why?
|
| Prostatic Neoplasms | 9 | 2023 | 1419 | 0.740 |
Why?
|
| Orientation | 1 | 2022 | 35 | 0.710 |
Why?
|
| Prostatic Hyperplasia | 5 | 2016 | 110 | 0.700 |
Why?
|
| NF-E2-Related Factor 2 | 3 | 2026 | 137 | 0.640 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2020 | 9 | 0.620 |
Why?
|
| Hypothyroidism | 1 | 2020 | 71 | 0.580 |
Why?
|
| Celiac Disease | 1 | 2020 | 73 | 0.580 |
Why?
|
| Papillomavirus Infections | 4 | 2023 | 394 | 0.530 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2026 | 821 | 0.510 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2023 | 750 | 0.460 |
Why?
|
| Cisplatin | 2 | 2026 | 274 | 0.410 |
Why?
|
| Prostate | 4 | 2016 | 404 | 0.400 |
Why?
|
| Biomarkers, Tumor | 5 | 2025 | 1586 | 0.390 |
Why?
|
| Immunoconjugates | 2 | 2025 | 41 | 0.390 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2025 | 145 | 0.380 |
Why?
|
| Cellular Senescence | 3 | 2014 | 217 | 0.370 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2025 | 478 | 0.360 |
Why?
|
| DNA Methylation | 3 | 2025 | 1077 | 0.360 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2024 | 81 | 0.350 |
Why?
|
| Osteopontin | 2 | 2026 | 55 | 0.350 |
Why?
|
| Alphapapillomavirus | 2 | 2022 | 49 | 0.350 |
Why?
|
| Receptors, Androgen | 4 | 2022 | 408 | 0.350 |
Why?
|
| Visual Perception | 2 | 2022 | 128 | 0.320 |
Why?
|
| Tumor Microenvironment | 4 | 2025 | 713 | 0.310 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2025 | 597 | 0.310 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2026 | 2026 | 0.290 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2023 | 155 | 0.270 |
Why?
|
| Humans | 47 | 2026 | 131163 | 0.260 |
Why?
|
| Cell Line, Tumor | 11 | 2026 | 3748 | 0.250 |
Why?
|
| Radiation Tolerance | 1 | 2025 | 61 | 0.220 |
Why?
|
| Prognosis | 6 | 2023 | 4886 | 0.220 |
Why?
|
| Interleukin-8 | 2 | 2014 | 200 | 0.220 |
Why?
|
| Space Perception | 2 | 2022 | 50 | 0.220 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 895 | 0.220 |
Why?
|
| Posture | 2 | 2022 | 138 | 0.210 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 1801 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2022 | 116 | 0.200 |
Why?
|
| Proteogenomics | 1 | 2025 | 111 | 0.200 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2024 | 89 | 0.200 |
Why?
|
| Homeodomain Proteins | 2 | 2017 | 555 | 0.200 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2024 | 167 | 0.200 |
Why?
|
| Male | 26 | 2025 | 64957 | 0.190 |
Why?
|
| Epithelial Cells | 5 | 2016 | 905 | 0.190 |
Why?
|
| Pancreatitis | 1 | 2024 | 139 | 0.190 |
Why?
|
| Smad Proteins | 1 | 2023 | 42 | 0.190 |
Why?
|
| CpG Islands | 2 | 2023 | 337 | 0.180 |
Why?
|
| Gene Rearrangement | 2 | 2024 | 323 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2025 | 1011 | 0.180 |
Why?
|
| Epigenesis, Genetic | 2 | 2025 | 757 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2002 | 108 | 0.180 |
Why?
|
| Mice | 14 | 2026 | 18301 | 0.170 |
Why?
|
| Glioblastoma | 1 | 2025 | 371 | 0.170 |
Why?
|
| Proprioception | 1 | 2021 | 17 | 0.170 |
Why?
|
| Multigene Family | 1 | 2002 | 290 | 0.170 |
Why?
|
| Animals | 18 | 2026 | 33912 | 0.160 |
Why?
|
| Signal Transduction | 7 | 2026 | 4686 | 0.160 |
Why?
|
| Transcriptome | 2 | 2024 | 1103 | 0.160 |
Why?
|
| Microbiota | 1 | 2025 | 438 | 0.160 |
Why?
|
| Ireland | 1 | 2020 | 33 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 4 | 2026 | 631 | 0.150 |
Why?
|
| Deoxycytidine | 1 | 2020 | 80 | 0.150 |
Why?
|
| Inactivation, Metabolic | 1 | 2019 | 25 | 0.150 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 1545 | 0.150 |
Why?
|
| Endometrium | 1 | 2023 | 292 | 0.150 |
Why?
|
| Epithelium | 2 | 2023 | 335 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 3436 | 0.150 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 388 | 0.150 |
Why?
|
| Psoriasis | 1 | 2020 | 48 | 0.150 |
Why?
|
| Interleukin-12 | 1 | 2020 | 125 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2019 | 18 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2019 | 13 | 0.150 |
Why?
|
| Transcription Factors | 3 | 2019 | 2406 | 0.150 |
Why?
|
| Antibodies, Bispecific | 1 | 2020 | 51 | 0.150 |
Why?
|
| Progesterone | 1 | 2021 | 439 | 0.150 |
Why?
|
| Estradiol | 1 | 2021 | 460 | 0.140 |
Why?
|
| Oncolytic Viruses | 1 | 2020 | 84 | 0.140 |
Why?
|
| Uterus | 1 | 2023 | 541 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 621 | 0.140 |
Why?
|
| Oncolytic Virotherapy | 1 | 2020 | 106 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 195 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 587 | 0.140 |
Why?
|
| Mice, Nude | 4 | 2026 | 700 | 0.130 |
Why?
|
| Female | 16 | 2025 | 70963 | 0.130 |
Why?
|
| Neoplasms | 2 | 2025 | 3016 | 0.130 |
Why?
|
| Oncogene Protein v-akt | 1 | 2017 | 32 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 480 | 0.130 |
Why?
|
| Adenoviridae | 1 | 2020 | 579 | 0.130 |
Why?
|
| RGS Proteins | 1 | 2017 | 47 | 0.130 |
Why?
|
| Homeostasis | 2 | 2023 | 712 | 0.130 |
Why?
|
| Papillomaviridae | 3 | 2022 | 180 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 972 | 0.120 |
Why?
|
| Aging | 1 | 2024 | 1242 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1336 | 0.120 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2017 | 67 | 0.120 |
Why?
|
| Collagen Type I | 1 | 2016 | 110 | 0.120 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2020 | 284 | 0.120 |
Why?
|
| Benzamides | 1 | 2017 | 127 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2017 | 200 | 0.120 |
Why?
|
| Aged | 7 | 2025 | 21025 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2023 | 993 | 0.120 |
Why?
|
| Middle Aged | 8 | 2025 | 28601 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 1306 | 0.120 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 2 | 2026 | 38 | 0.120 |
Why?
|
| Carcinoma, Papillary | 1 | 2016 | 91 | 0.120 |
Why?
|
| Deoxyguanosine | 1 | 2015 | 11 | 0.120 |
Why?
|
| Oncogenes | 1 | 2016 | 164 | 0.120 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 327 | 0.110 |
Why?
|
| Gene Targeting | 1 | 2016 | 169 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 232 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 6797 | 0.110 |
Why?
|
| Pyrroles | 1 | 2017 | 188 | 0.110 |
Why?
|
| Piperazines | 1 | 2017 | 265 | 0.110 |
Why?
|
| Germ Cells | 1 | 2016 | 201 | 0.110 |
Why?
|
| Comorbidity | 1 | 2020 | 1595 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1118 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1939 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2017 | 349 | 0.100 |
Why?
|
| Melanoma | 1 | 2021 | 931 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 3 | 2005 | 975 | 0.100 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2014 | 27 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 241 | 0.100 |
Why?
|
| Mannosidases | 1 | 2013 | 17 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2017 | 446 | 0.100 |
Why?
|
| Triterpenes | 1 | 2013 | 22 | 0.100 |
Why?
|
| Transcription Factor RelA | 1 | 2013 | 49 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 1591 | 0.090 |
Why?
|
| Prevalence | 1 | 2020 | 2701 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 960 | 0.090 |
Why?
|
| Macrophages | 1 | 2016 | 667 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 787 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 633 | 0.090 |
Why?
|
| Mice, Transgenic | 4 | 2021 | 2326 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 895 | 0.080 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 236 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 2602 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 587 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2022 | 17753 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2013 | 697 | 0.070 |
Why?
|
| Precision Medicine | 2 | 2023 | 388 | 0.070 |
Why?
|
| Cell Proliferation | 4 | 2017 | 2465 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2025 | 4697 | 0.070 |
Why?
|
| Cytokines | 1 | 2014 | 1339 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2009 | 435 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2020 | 585 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2023 | 2550 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2021 | 905 | 0.060 |
Why?
|
| Adult | 3 | 2025 | 31282 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2013 | 889 | 0.060 |
Why?
|
| Biomarkers | 3 | 2022 | 3385 | 0.060 |
Why?
|
| Monosomy | 1 | 2005 | 24 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2017 | 240 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2005 | 77 | 0.060 |
Why?
|
| Immunotherapy | 2 | 2021 | 768 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 1 | 2025 | 179 | 0.060 |
Why?
|
| Young Adult | 1 | 2020 | 10103 | 0.060 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2025 | 82 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2025 | 101 | 0.060 |
Why?
|
| Fibroblast Growth Factors | 2 | 2004 | 172 | 0.060 |
Why?
|
| Paraffin Embedding | 1 | 2025 | 40 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 1287 | 0.060 |
Why?
|
| Tissue Fixation | 1 | 2025 | 38 | 0.060 |
Why?
|
| Formaldehyde | 1 | 2025 | 49 | 0.050 |
Why?
|
| Survival Rate | 2 | 2021 | 2114 | 0.050 |
Why?
|
| Transcriptional Regulator ERG | 2 | 2016 | 40 | 0.050 |
Why?
|
| Pancreatitis, Alcoholic | 1 | 2024 | 5 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 982 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2025 | 223 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2025 | 335 | 0.050 |
Why?
|
| Histone Deacetylases | 1 | 2024 | 130 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2022 | 825 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2026 | 713 | 0.050 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2003 | 8 | 0.050 |
Why?
|
| Stromal Cells | 2 | 2016 | 316 | 0.050 |
Why?
|
| Inflammation | 2 | 2024 | 1489 | 0.050 |
Why?
|
| Age of Onset | 1 | 2025 | 592 | 0.050 |
Why?
|
| Kenya | 1 | 2023 | 60 | 0.050 |
Why?
|
| Pancreas | 1 | 2024 | 217 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 135 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1826 | 0.050 |
Why?
|
| Ethanol | 1 | 2024 | 170 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2022 | 8 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 9 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2003 | 130 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 1373 | 0.050 |
Why?
|
| Epigenomics | 1 | 2023 | 181 | 0.050 |
Why?
|
| Physical Chromosome Mapping | 1 | 2002 | 55 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 2395 | 0.050 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2002 | 87 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 224 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2004 | 448 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2002 | 277 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 3464 | 0.040 |
Why?
|
| Disease Progression | 2 | 2019 | 2200 | 0.040 |
Why?
|
| Bacteria | 1 | 2025 | 521 | 0.040 |
Why?
|
| Administration, Intravaginal | 1 | 2021 | 10 | 0.040 |
Why?
|
| Immunity | 1 | 2022 | 178 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1618 | 0.040 |
Why?
|
| Adolescent | 1 | 2020 | 20987 | 0.040 |
Why?
|
| Proteomics | 1 | 2025 | 615 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 72 | 0.040 |
Why?
|
| Acute Disease | 1 | 2024 | 1153 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2002 | 582 | 0.040 |
Why?
|
| Atrophy | 1 | 2021 | 247 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 237 | 0.040 |
Why?
|
| Postmenopause | 1 | 2021 | 137 | 0.040 |
Why?
|
| Emergencies | 1 | 2021 | 171 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 344 | 0.040 |
Why?
|
| Transfection | 2 | 2017 | 962 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2002 | 516 | 0.040 |
Why?
|
| Glucuronic Acid | 1 | 2019 | 12 | 0.040 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2019 | 15 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 149 | 0.040 |
Why?
|
| S-Adenosylmethionine | 1 | 2019 | 26 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 2833 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 64 | 0.040 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2019 | 12 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 299 | 0.040 |
Why?
|
| Vagina | 1 | 2021 | 208 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2022 | 387 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2002 | 644 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 235 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 801 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 386 | 0.030 |
Why?
|
| Gene Expression | 1 | 2002 | 1481 | 0.030 |
Why?
|
| Apoptosis | 1 | 2024 | 1827 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2023 | 1075 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2019 | 170 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2021 | 677 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1626 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1216 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 289 | 0.030 |
Why?
|
| Second Harmonic Generation Microscopy | 1 | 2016 | 5 | 0.030 |
Why?
|
| Interleukin-1alpha | 1 | 2016 | 11 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 191 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1590 | 0.030 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2016 | 31 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2016 | 84 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 52 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2016 | 63 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2019 | 484 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2017 | 136 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 558 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 112 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 1207 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 369 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 156 | 0.030 |
Why?
|
| NADPH Oxidase 4 | 1 | 2015 | 13 | 0.030 |
Why?
|
| Metabolomics | 1 | 2019 | 501 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2025 | 5063 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2023 | 1928 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 423 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2015 | 109 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 229 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2015 | 242 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 4738 | 0.030 |
Why?
|
| Cathepsin D | 1 | 2014 | 16 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1071 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 978 | 0.030 |
Why?
|
| Phenotype | 2 | 2014 | 4497 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 67 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 992 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2014 | 144 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2013 | 83 | 0.020 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2013 | 8 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 1571 | 0.020 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 209 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1410 | 0.020 |
Why?
|
| DNA Damage | 1 | 2015 | 511 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2013 | 686 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 5196 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 710 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 3819 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2015 | 791 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 6099 | 0.020 |
Why?
|
| Registries | 1 | 2016 | 1634 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 2323 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 3686 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2885 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 6196 | 0.020 |
Why?
|
| United States | 1 | 2021 | 12072 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2005 | 123 | 0.010 |
Why?
|
| Karyotyping | 1 | 2005 | 308 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 204 | 0.010 |
Why?
|
| Infant | 1 | 2020 | 13352 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2004 | 48 | 0.010 |
Why?
|
| Myeloproliferative Disorders | 1 | 2005 | 91 | 0.010 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2004 | 57 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 12936 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2005 | 1046 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 776 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 775 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2005 | 653 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 1205 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2005 | 614 | 0.010 |
Why?
|